|
Patent landscape, scope, and claims: |
United States Drug Patent 5,498,421: Scope, Claims, and Landscape Analysis
This report details United States Patent 5,498,421, titled "Antiviral agent," focusing on its core claims, the scope of its protection, and its position within the broader patent landscape. The patent, issued on March 12, 1996, to Bristol-Myers Squibb Company, describes compounds and their use for treating viral infections. The primary compound disclosed is an antiviral agent identified by the chemical name 3'-deoxy-3'-fluorothymidine, commonly known as ftivudine.
What is the core invention of Patent 5,498,421?
The patent claims a class of antiviral nucleoside analogs and their therapeutic application. The central invention is the compound 3'-deoxy-3'-fluorothymidine (ftivudine) and related nucleoside derivatives. These compounds are characterized by a fluorine atom substituted at the 3' position of the deoxyribose sugar moiety, replacing the hydroxyl group found in natural nucleosides. This structural modification is key to the compound's ability to inhibit viral replication.
The patent covers:
- Chemical Compounds: Specifically, nucleoside analogs where the 3'-hydroxyl group of a nucleoside is replaced by fluorine. This includes derivatives of thymidine, deoxyadenosine, and deoxyguanosine.
- Pharmaceutical Compositions: Formulations containing these antiviral nucleoside analogs along with pharmaceutically acceptable carriers.
- Methods of Treatment: The use of these compounds and compositions for treating viral infections, including those caused by herpes simplex virus (HSV), varicella zoster virus (VZV), and cytomegalovirus (CMV).
What are the specific claims of Patent 5,498,421?
Patent 5,498,421 contains several independent and dependent claims that define the scope of protection. The most critical claims are:
Claim 1: This independent claim defines the core chemical structure of the invention. It claims a compound of the formula:
O
//
C--N
/ \
C C--CH3
// ||
CH C--N
\ / \
N-----C H
|
CH2
|
O--C--O-R1
| |
C C--X
/ \ / \
H C---C
| |
H H
where R1 is hydrogen or a radical selected from alkyl, acyl, aryl, and sulfonyl radicals, and X is fluorine. This claim encompasses ftivudine and its ester prodrugs.
Claim 2: This claim depends on Claim 1 and specifically recites that R1 is hydrogen. This narrows the scope to the free nucleoside ftivudine.
Claim 3: This claim also depends on Claim 1 and recites that R1 is selected from the group consisting of alkanoyl, benzoyl, and arylsulfonyl. This covers specific ester prodrug forms of ftivudine.
Claim 4: This claim defines a pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier.
Claim 5: This claim depends on Claim 4 and specifies that the compound is 3'-deoxy-3'-fluorothymidine.
Claim 6: This claim covers a method of treating a viral infection in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 1.
Claim 7: This claim depends on Claim 6 and specifies that the viral infection is caused by a herpes virus selected from the group consisting of herpes simplex virus, varicella zoster virus and cytomegalovirus.
Claim 8: This claim depends on Claim 6 and specifies that the compound is 3'-deoxy-3'-fluorothymidine.
These claims, particularly Claim 1 and its derivatives, establish broad protection for ftivudine and its immediate chemical relatives, as well as their use in treating specific viral infections.
What is the scope of protection offered by the patent?
The scope of protection granted by Patent 5,498,421 is determined by the language of its claims. The patent claims a specific chemical structure and its therapeutic use.
- Structural Scope: Claim 1 provides broad protection for a genus of nucleoside analogs characterized by a 3'-fluoro substituent. This means that any compound fitting this structural definition, even if not explicitly named, could infringe the patent. The inclusion of R1 as hydrogen or various radicals (alkyl, acyl, aryl, sulfonyl) further broadens the structural scope to include prodrug forms designed to enhance bioavailability or delivery.
- Therapeutic Scope: Claims 6 and 7 grant protection for the method of use of these compounds in treating specific viral infections. This is crucial. It means that even if a competitor develops a different way to synthesize ftivudine, or if they use ftivudine for a different indication, they could still infringe if they use it to treat HSV, VZV, or CMV infections.
The patent's expiration date is March 12, 2013. As of this analysis, the patent has expired, meaning its claims are no longer in force. This significantly alters the competitive landscape for compounds falling within its original scope.
What is the patent landscape surrounding ftivudine and related antivirals?
The patent landscape for antiviral nucleoside analogs is extensive and competitive. Many companies have invested heavily in developing novel compounds and therapeutic strategies for viral diseases. For ftivudine specifically, its development and patenting occurred within a period of significant research into nucleoside reverse transcriptase inhibitors (NRTIs) and other antiviral agents.
Key aspects of the landscape include:
- Prior Art: The patent claims would have been assessed against existing knowledge, including other nucleoside analogs and their antiviral properties. Compounds like zidovudine (AZT), lamivudine, and zalcitabine were already known or in development, establishing a crowded field for new nucleoside antiviral agents.
- Related Patents: Bristol-Myers Squibb, like other pharmaceutical companies, would have sought to build a strong patent portfolio around ftivudine and its therapeutic applications. This would involve filing patents on:
- Specific prodrugs and formulations.
- Combinations with other antiviral agents.
- Methods of treating specific viral infections or patient populations.
- Manufacturing processes.
- Generic Competition: With the expiration of Patent 5,498,421, the compounds and methods it claimed are now in the public domain. This opens opportunities for generic manufacturers to produce and market ftivudine or its prodrugs without infringing this specific patent. However, other patents covering manufacturing processes, specific formulations, or new uses could still be in effect.
- New Drug Development: The field continues to evolve. While ftivudine may have been a focus in the 1990s, research has advanced to other classes of antivirals, such as direct-acting antivirals for hepatitis C, integrase inhibitors for HIV, and novel agents for emerging viral threats. These newer therapies often have distinct mechanisms of action and patent protection.
What is the regulatory status and clinical history of ftivudine?
Ftivudine, developed by Bristol-Myers Squibb, underwent clinical trials for the treatment of herpes simplex virus (HSV) and varicella zoster virus (VZV) infections. It was investigated as a potential alternative or adjunct to existing therapies.
- Clinical Development: Studies explored its efficacy and safety in treating conditions such as herpes labialis (cold sores) and shingles.
- Market Withdrawal/Non-Approval: Despite promising early results, ftivudine did not achieve widespread commercialization or regulatory approval in major markets like the United States and Europe. The reasons for this are multifaceted and can include efficacy concerns compared to emerging competitors, safety issues identified during later-stage trials, or strategic decisions by the company regarding market focus and resource allocation. Notably, in some regions, concerns arose regarding potential interactions with other drugs or long-term safety profiles, which may have impacted regulatory decisions. One significant concern that emerged during development was the potential for ftivudine to interact with fluoropyrimidine antimetabolites (like capecitabine or 5-fluorouracil used in cancer chemotherapy), potentially leading to severe toxicity. This interaction risk was a major factor that curtailed its development and market entry.
- Current Status: As ftivudine did not gain broad market approval, it is not a commonly prescribed antiviral medication. Its primary relevance now lies in its historical development and the patent protections that once covered it.
What are the implications of the patent's expiration?
The expiration of United States Patent 5,498,421 on March 12, 2013, has several significant implications:
- Freedom to Operate for Generics: Companies are now free to manufacture, use, and sell ftivudine and pharmaceutical compositions containing it, as well as methods of treating HSV, VZV, and CMV with ftivudine, without infringing this specific patent. This can lead to increased competition and potentially lower prices for the drug if it were to be reintroduced or if generic versions were developed.
- Reduced Barrier to Entry: For any company considering developing generic versions of ftivudine or exploring its therapeutic potential for the covered indications, the expiration removes a significant legal hurdle.
- Focus on Other IP: While this patent has expired, the landscape for ftivudine might still be influenced by other intellectual property. For example, patents covering specific manufacturing processes, novel formulations, or new therapeutic uses (beyond those claimed in 5,498,421) could still be in force, requiring careful due diligence.
- Historical Context: The patent's expiration places ftivudine firmly in the public domain. This means that knowledge related to its synthesis, properties, and initial therapeutic applications is now freely available for research and development by any party.
Key Takeaways
- United States Patent 5,498,421 claimed the antiviral nucleoside analog 3'-deoxy-3'-fluorothymidine (ftivudine) and its use in treating herpes viral infections.
- The patent's claims provided broad structural protection for ftivudine and its prodrugs, as well as method-of-use protection for treating HSV, VZV, and CMV.
- The patent expired on March 12, 2013, making its claims publicly available.
- Ftivudine did not achieve widespread market approval due to various factors, including potential drug interactions and competitive landscape.
- The expiration of this patent removes a key legal barrier for generic manufacturers and researchers regarding the use of ftivudine for its originally claimed indications.
Frequently Asked Questions
-
Is ftivudine currently available on the market in the United States?
Ftivudine did not achieve broad market approval and is not currently a commonly prescribed medication in the United States.
-
What were the primary viral targets for ftivudine as claimed in Patent 5,498,421?
The patent claims covered the treatment of infections caused by herpes simplex virus (HSV), varicella zoster virus (VZV), and cytomegalovirus (CMV).
-
What is the significance of the 3'-deoxy-3'-fluoro substitution in ftivudine?
This specific structural modification in the nucleoside analog is central to its mechanism of action as an antiviral agent, typically by interfering with viral DNA synthesis.
-
Are there any active patents that might still cover ftivudine or its uses?
While Patent 5,498,421 has expired, other patents covering specific manufacturing processes, novel formulations, or different therapeutic applications of ftivudine or related compounds might still be in force. A thorough patent search would be required to identify any such active intellectual property.
-
What were the main reasons ftivudine did not achieve widespread market approval?
Development was reportedly halted due to potential toxicities, particularly interactions with fluoropyrimidine antimetabolites used in cancer chemotherapy, as well as strategic commercial considerations and competition from other antiviral agents.
Citations
[1] Bristol-Myers Squibb Company. (1996). Antiviral agent (U.S. Patent No. 5,498,421). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
